Author(s):
Manikandan Arumugam, Vinay Kumar Gupta, Hemalatha Siva
Email(s):
shemalatha.phe@iitbhu.ac.in
DOI:
10.52711/0974-360X.2025.00621 
Address:
Manikandan Arumugam1, Vinay Kumar Gupta2, Hemalatha Siva1*
1Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh, India.
2Assistant Drugs Controller (India), CDSCO, Zonal Office, Hyderabad, Telangana, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 9,
Year - 2025
ABSTRACT:
Introduction: India faces significant challenges in providing access to basic healthcare and necessary medications to its large population, despite the remarkable expansion of the country's pharmaceutical sector. About 20 percent of drugs that are procured fail in the quality control tests, impacting public confidence. With a focus on the need for multifaceted assessments to improve drug availability, quality, and public confidence, this study aims to evaluate the efficiency, effectiveness, and quality of public drug procurement systems across seven states in India by developing a specific set of performance indicators. Methodology: Using 22 predetermined parameters that focus on efficiency, cost-effectiveness, and quality, a quantitative study was undertaken to evaluate the performance of public drug procurement systems in seven sample states during the year 2021-2022. Data was collected using a data collection tool, telephone interviews, and references to the respective medical corporation's website. The whole data collection process and the scoring framework were validated by performing a pilot study on two of the study sample states to ensure robustness across diverse regional states. Findings: The study revealed considerable differences in efficiency, cost-effectiveness, and drug quality-related performance parameters. Among the sample states, Tamil Nadu and Kerala exhibited superior drug procurement performance. Conversely, states like Odisha and Chhattisgarh faced challenges in budget allocation and compliance, underscoring the need for policy reforms. This study also highlights the need to consider geographical and financial factors for a comprehensive evaluation and enhancement of public drug procurement efficiency throughout India. Conclusion: This study examines the strengths and weaknesses of public drug procurement processes in seven states. The study also underscores the necessity for policy reforms and collaborative initiatives among various stakeholders to improve procurement processes. By implementing comprehensive evaluation methodologies and adhering to a benchmark model, policymakers can reduce substandard medications and improve public health outcomes.
Cite this article:
Manikandan Arumugam, Vinay Kumar Gupta, Hemalatha Siva. Public Drug Procurement and Distribution in India: A Performance Assessment Study Across Seven different states from Diverse Geographic Regions. Research Journal of Pharmacy and Technology. 2025;18(9):4329-6. doi: 10.52711/0974-360X.2025.00621
Cite(Electronic):
Manikandan Arumugam, Vinay Kumar Gupta, Hemalatha Siva. Public Drug Procurement and Distribution in India: A Performance Assessment Study Across Seven different states from Diverse Geographic Regions. Research Journal of Pharmacy and Technology. 2025;18(9):4329-6. doi: 10.52711/0974-360X.2025.00621 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-9-41
REFERENCES:
1. Singh PV et al. Understanding public drug procurement in India: a comparative qualitative study of five Indian states. BMJ Open. 2013; 3(2): e001987.
2. Thombare S, Nashikkar R, Patil R. Market Dynamics: Examining Drug Sales in Panvel. Asian Journal of Management. 2024; 15(2): 2.
3. Chan M. Ten years in public health, 2007–2017: report by Dr Margaret Chan, Director-General. World Health Organization. 2017;
4. United Nations Development Group. Indicators for monitoring the millennium development goals: definitions, rationale, concepts and sources. Vol. 95. United Nations Publications; 2003.
5. Kulshreshth P. A Temporal Analysis of India’s Public Health Expenditure. Health N Hav. 2021;
6. Kaur H, Shah A, Srivastava S. How elements of the Indian state purchase drugs. 2021.
7. Weir RE et al. Variability in the content of Indian generic ciprofloxacin eye drops. British Journal of Ophthalmology. 2005; 89(9): 1094–6.
8. Evenett SJ, Hoekman BM. International cooperation and the reform of public procurement policies. Vol. 4663. World Bank Publications; 2005.
9. Gavarkar P et al. Comparative Study of Generic and Branded Creams of Clotrimazole. Asian Journal of Research in Pharmaceutical Science. 2016; 6(4): 205–7.
10. Das S, Bhakta T. A Survey to the Extent of Spurious Drugs in the Market of India. Research Journal of Pharmacognosy and Phytochemistry. 2018; 10(3): 233–40.
11. Khanday SA. Globalization: The Third Eye in Drug Marketing. Research Journal of Humanities and Social Sciences. 2019; 10(2): 383–90.
12. Verma DRK. Generic medicines: Core issues and legal mechanism. International Journal of Reviews and Research in Social Sciences. 2019; 7(2): 405–14.
13. Khan Y et al. A Review on Marketing of OTC Drugs. Asian Journal of Research in Pharmaceutical Science. 2013; 3(2): 72–8.
14. Kanthe R. Consumer Buying Behavior and Non-Prescriptive Drugs Shopping In Sangli. Asian Journal of Management. 2010; 1(2): 55–60.
15. Nikam NR, Vakhariya RR, Magdum CS. Generic Vs. Brand Medicines: An Overview. Asian Journal of Pharmaceutical Research. 2019; 9(2): 109–15.
16. Jadhav CA, Vikhe DN, Jadhav RS. Global and domestic market of herbal medicines: A review. Research Journal of Science and Technology. 2020; 12(4): 327–30.
17. Bansal JR et al. Availability of Standard Quality Drugs Ensured in India: Stringent Drug Regulations and Up Graded Regulatory Mechanism. Res J Pharm Technol. 2024; 17(7): 3079–83.
18. Lewis M, Pettersson Gelander G. Governance in health care delivery: raising performance. World Bank Policy Research Working Paper. 2009; (5074).
19. Fiszbein A, Ringold D, Rogers FH. Making services work: indicators, assessments, and benchmarking of the quality and governance of public service delivery in the human development sectors. World Bank policy research working paper. 2011; (5690).
20. Bradley MM. Ironing Out Anemia: Assessing the Role of Marketplace Factors and Government Investment Incentives in Shaping East African Pharmaceutical Markets. 2021;
21. Saaida M. Collaborating for Change: The Power of Multilateral Cooperation in SDGs. 2023; 20; 1: 1–26.
22. Manning L, Soon JM. Developing systems to control food adulteration. Food Policy. 2014; 49: 23–32.
23. Acharya AK. Toward establishing a universal basic health norm. Ethics Int Aff. 2004; 18(3): 65–78.